New Phase IIb data from Eisai and Biogen provide an insight into the impact of the firm’s most advanced Alzheimer’s disease (AD) candidate. 11 November 2021
Highlighting research presented at the Infectious Diseases Week (IDWeek) annual congress, Brighton, UK-based biotech Destiny Pharma says there is “strong suppor 18 October 2021
In multiple sclerosis (MS), new data for Ocrevus (ocrelizumab) should help physicians understand the long-term characteristics of treatment with the monoclonal 13 October 2021
Tolebrutinib, an investigational oral Bruton’s tyrosine kinase (BTK) inhibitor under development by Sanofi (Euronext: SAN) has shown favorable levels of tolerab 13 October 2021
Johnson & Johnson has announced a new analysis of Stelara (ustekinumab), using safety data from 13 clinical studies across approved indications. 6 October 2021
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.